Could Frizzled proteins lead to new cancer drugs? (Melbourne)
A new way to fight drug-resistant bacteria (Canberra)
- Photos and HD footage available
- Alisa Glukhova full biography, photos, videos and HD footage
- Si Ming Man full biography, photos, videos and HD footage
Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years, to investigate new ways to fight two of the world’s biggest health challenges: cancer and infectious diseases. The Fellowships will be presented at the Australian Academy for Health and Medical Research Online Scientific Meeting 2020 on Thursday 15 October.
Dr Alisa Glukhova is investigating a fundamental cell communication system that guides the growth of embryos but, when it goes wrong, can contribute to cancer and other diseases. By determining the structure and shape of a signal receptor in this system, known as the Frizzled protein, she hopes to create a path to new kinds of cancer drugs.
We know very little about how Frizzled proteins and cell signalling systems work – a gap in our knowledge Alisa hopes to close thanks to her $1.25 million CSL Centenary Fellowship.
Dr Glukhova is a structural biologist at the Walter and Eliza Hall Institute of Medical Research in Melbourne.
Professor Si Ming Man is investigating disease-fighting proteins produced by the immune system and how they might be harnessed to fight infectious diseases.
The answers could lead to alternatives to over-used and increasingly ineffective antibiotics, providing new ways to combat multidrug-resistant microbes.
Si Ming will use his $1.25 million CSL Centenary Fellowship to study a particular family of killer immune system proteins known as guanylate-binding proteins.
Professor Man is an infectious diseases researcher at the John Curtin School of Medical Research, Australian National University, in Canberra.
CSL Chief Scientific Officer Dr Andrew Nash said that Dr Glukhova and Professor Man both work in fields of global significance.
“Alisa’s and Si Ming’s work epitomises the ethos of the CSL Centenary Fellowships. They are each seeking a deeper understanding of key proteins—vital molecules for all living systems—that could transform how we fight infectious diseases and cancer,” he said.
“It is this long-term vision that the CSL Fellowships aim to support by providing funding stability for leading mid-career Australian researchers.”
– ends –
About the CSL Centenary Fellowships
The Fellowships are competitively selected, high-value grants available to mid-career Australians who wish to continue a career in medical research in Australia. They were established to mark 100 years since the establishment of CSL in 1916. Two individual, five-year, A$1.25 million fellowships are awarded each calendar year. www.cslfellowships.com.au.
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides life-saving products to more than 70 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSL For more information about CSL Limited, visit www.csl.com.au.